Jerónimo Rafael Rodríguez Cid: EGFR mutated patients doesnt have any benefit with immunotherapy in TKI’s resistant tumors

Jerónimo Rafael Rodríguez Cid, Medical Oncologist in CDMX, shared a post on X:

“We published in JCO by ASCO the analysis of this trial which reflects that EGFR mutated (lung cancer) patients doesn’t have any benefit of treatment with immunotherapy in TKI’s resistant tumors.

We will never stop trying.”

Jerónimo Rafael Rodríguez Cid: EGFR mutated patients doesnt have any benefit with immunotherapy in TKI's resistant tumors

Source: Jerónimo Rafael Rodríguez Cid/X

Insight

ASCO JCO cancer EGFR immunotherapy Jerónimo Rafael Rodríguez Cid Lung cancer OncoDaily Oncology TKI